肺癌筛查与戒烟临床试验:SCALE协作组方法学解读
本文介绍SCALE协作组框架下8项临床试验(7项由美国国家癌症研究所资助,1项由退伍军人健康管理局资助)的设计方法学问题。文章聚焦临床工作流程、受试者入选标准、筛查指征、评估内容、戒烟意愿及治疗实施方式与剂量等影响烟草治疗结局的因素,探讨如何在肺癌筛查情境中最大化戒烟效果。
要点
- SCALE协作组整合8项临床试验,研究肺癌筛查情境下的戒烟干预系统设计。
- 试验设计需考虑临床工作流程、受试者资格、筛查指征及治疗剂量等关键要素。
- 肺癌筛查提供「可教育时机」,需协调戒烟治疗与筛查相关临床事件。
核心结论
- 肺癌筛查为降低肺癌相关发病率和死亡率提供了新机遇,有效的戒烟治疗可放大这一获益。
- SCALE协作组的团队合作有望最大化从这些临床试验中获得的知识。
研究设计与样本
- 本文为SCALE协作组的方法学描述文章,该协作组由8项临床试验组成,其中7项由美国国家癌症研究所资助,1项由退伍军人健康管理局资助。
主要发现
- 文章描述了与临床试验设计相关的方法学问题:临床工作流程、受试者入选标准、筛查指征(基线或年度重复筛查)、评估内容、戒烟意愿以及治疗实施方式和剂量。
- 烟草干预需考虑肺癌筛查提供的「可教育时机」、如何纳入阳性和阴性筛查结果,以及戒烟治疗与肺癌筛查相关临床事件的协调。
- 感知肺癌风险和烟草治疗成本等独特数据元素受到关注。
临床怎么用
- 在肺癌筛查系统中设计戒烟干预时,需综合考虑临床工作流程、受试者资格、筛查指征及治疗实施方式与剂量等因素。
- 戒烟治疗应与肺癌筛查的临床事件相协调,并利用筛查结果(阳性或阴性)作为干预契机。
局限性
- 文章为方法学描述,未报告各试验的具体结局数据。
- 原文未报告样本量、效应量、置信区间或P值等定量结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
National recommendations for lung cancer screening for former and current smokers aged 55-80 years with a 30-pack-year smoking history create demand to implement efficient and effective systems to offer smoking cessation on a large scale. These older, high-risk smokers differ from participants in past clinical trials of behavioral and pharmacologic interventions for tobacco dependence. There is a gap in knowledge about how best to design systems to extend reach and treatments to maximize smoking cessation in the context of lung cancer screening. Eight clinical trials, seven funded by the National Cancer Institute and one by the Veterans Health Administration, address this gap and form the SCALE (Smoking Cessation within the Context of Lung Cancer Screening) collaboration. This paper describes methodological issues related to the design of these clinical trials: clinical workflow, participant eligibility criteria, screening indication (baseline or annual repeat screen), assessment content, interest in stopping smoking, and treatment delivery method and dose, all of which will affect tobacco treatment outcomes. Tobacco interventions consider the "teachable moment" offered by lung cancer screening, how to incorporate positive and negative screening results, and coordination of smoking cessation treatment with clinical events associated with lung cancer screening. Unique data elements, such as perceived risk of lung cancer and costs of tobacco treatment, are of interest. Lung cancer screening presents a new and promising opportunity to reduce morbidity and mortality resulting from lung cancer that can be amplified by effective smoking cessation treatment. SCALE teamwork and collaboration promise to maximize knowledge gained from the clinical trials.
引用
- Joseph AM, Rothman AJ, Almirall D, et al. Lung Cancer Screening and Smoking Cessation Clinical Trials. SCALE (Smoking Cessation within the Context of Lung Cancer Screening) Collaboration. Am J Respir Crit Care Med. 2018. PMID: 28977754. doi:10.1164/rccm.201705-0909CI
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。